Nivolumab shows signs of superior response rate compared to standard chemo in advanced melanoma

(European Society for Medical Oncology) The monoclonal antibody nivolumab achieves superior response rates and a longer duration of response than standard chemotherapy in patients whose melanoma has progressed after treatment with ipilimumab, according to phase III data presented at the ESMO 2014 Congress in Madrid, Spain.